Gianni Bisogno, Riccardo Riccardi, Antonio Ruggiero, Giampaolo Arcamone, Arcangelo Prete, Gianmarco Surico, Massimo Provenzi, Patrizia Bertolini, Paolo Paolucci and Modesto Carli Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma Cancer 106
Article first published online: 20 DEC 2005 | DOI: 10.1002/cncr.21629
A phase II study of irinotecan administered intravenously every day for 5 days in 2 consecutive weeks, conducted in pediatric patients with relapsed soft tissue sarcoma, demonstrated an interesting response rate in a population of heavily pretreated patients, especially in the subset of patients with peripheral primitive neuroectodermal tumor.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.